Celgene International Sárl (CELG) Two Studies Evaluating the Combination of REVLIMID® and rituximab in Non-Hodgkin’s Lymphomas Presented at International Conference on Malignant Lymphoma
6/20/2013 9:09:25 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that results from two studies evaluating the combination of REVLIMID® (lenalidomide) and rituximab in various non-Hodgkin’s lymphomas were presented at the 12th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland.
Help employers find you! Check out all the jobs and post your resume.
comments powered by